Latest news with #LeMaitre
Yahoo
16-05-2025
- Business
- Yahoo
LMAT Q1 Earnings Call: Sales Growth Outpaces Expectations, Margin Pressures Addressed
Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 12% year on year to $59.87 million. The company expects next quarter's revenue to be around $62.5 million, close to analysts' estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts' consensus estimates. Is now the time to buy LMAT? Find out in our full research report (it's free). Revenue: $59.87 million vs analyst estimates of $57.75 million (12% year-on-year growth, 3.7% beat) EPS (GAAP): $0.48 vs analyst expectations of $0.50 (4.6% miss) Adjusted EBITDA: $16.78 million vs analyst estimates of $15.57 million (28% margin, 7.8% beat) The company lifted its revenue guidance for the full year to $245.5 million at the midpoint from $239.1 million, a 2.7% increase EPS (GAAP) guidance for the full year is $2.16 at the midpoint, missing analyst estimates by 3.5% Operating Margin: 21.1%, down from 22.2% in the same quarter last year Free Cash Flow Margin: 12.8%, up from 6.9% in the same quarter last year Organic Revenue rose 13% year on year (11% in the same quarter last year) Market Capitalization: $1.88 billion LeMaitre's first quarter results were driven by broad-based sales growth across all product categories and geographies, fueled by strong demand for vascular grafts and carotid shunts. Management attributed the outperformance to price increases, expansion of the direct sales force, and new international offices. CEO George LeMaitre emphasized, 'Growth was led by grafts up 17% and carotid shunts up 14%,' and noted record sales in every major product category. Looking ahead, management raised full-year revenue guidance, citing sustained sales momentum, the launch of new international offices, and recently secured regulatory approvals. While the company expects to benefit from a growing sales organization and upcoming product launches, management was cautious about potential margin headwinds from product mix and tariffs. CFO Dorian LeBlanc stated that moving away from the Elutia patch distribution agreement should improve organic growth and margins in the coming quarters. LeMaitre's management identified several operational and market drivers behind the quarter's results and discussed strategic moves to sustain momentum. Direct Sales Force Expansion: The company increased its on-payroll sales representatives to 164, aiming for 170 by year-end. Management highlighted that direct sales are their primary growth engine, with new hires expected to support continued market penetration. International Office Openings: New sales offices in Switzerland, Portugal, and soon the Czech Republic are expected to streamline distribution and improve sales in these regions. The Zurich office, for example, is designed to reduce customs complexity for Swiss hospitals, and direct offices have historically led to higher sales performance. Autograft Regulatory Progress: The company received a Medical Device Regulation (MDR) CE mark for its Artegraft product, enabling a European launch. Artegraft, previously the company's largest U.S. product, is now positioned for growth internationally, with additional approvals anticipated in Australia, Canada, Singapore, and Korea. Product Mix and Margin Impact: A shift toward higher sales in the graft category, which carries a lower gross margin than other products, contributed to a slight year-on-year decrease in operating margin. Management explained that price increases and reduced inventory scrap partially offset this impact. Elutia Patch Exit: LeMaitre exited its distribution agreement with Elutia to focus on its own biologics. This move is expected to improve organic growth rates and gross margins, as the discontinued product had been declining and carried lower margins than proprietary offerings. Management expects continued revenue growth, supported by an expanded sales force, new product approvals, and a broader international presence. However, product mix, tariffs, and competitive dynamics may create margin variability in upcoming quarters. Sales Force Investments: The addition of new sales representatives and managers is anticipated to drive higher revenues, with management indicating that new hires reach productivity levels comparable to veteran employees more quickly than in previous years. Tariff and Trade Risks: While LeMaitre manufactures all products in the United States, potential retaliatory tariffs remain a risk for international sales. Management believes they can mitigate much of the impact through price increases and low substitution risk due to niche product offerings. Product Launches and Regulatory Approvals: New product launches, such as the European rollout of Artegraft and expected approvals for RestoreFlow allografts in Ireland or Germany, are likely to support revenue growth and help offset potential margin headwinds from product mix changes. Suraj Kalia (Oppenheimer): Asked what gives management confidence to raise guidance given global uncertainties such as tariffs. CEO George LeMaitre cited stronger-than-expected Q1 results, effective price increases, and the positive impact of exiting the Elutia distribution. Rick Wise (Stifel): Inquired about the sustainability of price and volume growth. Management explained that Q1 saw a 9% price increase and 4% unit growth, but cautioned that future quarters may not maintain the same pace. Michael Saccone (Jefferies): Sought clarification on margin pressures. Management attributed margin contraction to higher sales in grafts, which have lower corporate-average margins, and highlighted that product mix shifts were a primary factor. Frank Tarkinen (Lake Street): Questioned when the expanded sales force would contribute to operating leverage. CFO Dorian LeBlanc noted that new reps ramp up productivity faster than in the past, and sales ramp and margin improvement are expected in the second half of the year. Brett Fishbin (KeyBanc): Asked about the impact of tariffs and the rationale for discontinuing the Elutia agreement. Management confirmed that expected tariff costs and mitigation strategies are factored into guidance, and explained that exiting Elutia removes a declining product and should support organic growth. In the coming quarters, the StockStory team will be monitoring (1) the impact of new direct sales offices and additional sales hires on revenue growth, (2) the European launch and adoption of Artegraft following regulatory approval, and (3) progress toward RestoreFlow allograft approvals in key European markets. Additionally, we will track management's ability to navigate product mix challenges and tariff risks while maintaining or expanding margins. LeMaitre currently trades at a forward P/E ratio of 35.9×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Yahoo
07-05-2025
- Business
- Yahoo
Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables
Let's dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts' consensus estimates by 1.8% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.8% since the latest earnings results. LeMaitre (NASDAQ:LMAT) Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year. This print exceeded analysts' expectations by 3.7%. Despite the top-line beat, it was still a mixed quarter for the company with full-year revenue guidance exceeding analysts' expectations but a miss of analysts' EPS estimates. Chairman/CEO George LeMaitre said, 'Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.' LeMaitre Total Revenue LeMaitre achieved the biggest analyst estimates beat and highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 12.8% since reporting and currently trades at $80.52. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it's free.
Yahoo
02-05-2025
- Business
- Yahoo
Why LeMaitre (LMAT) Shares Are Sliding Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 12.2% in the afternoon session after the company reported weak first quarter 2025 results with a significant miss on full-year EPS guidance and underwhelming EPS guidance for next quarter. On the other hand, LeMaitre's full-year revenue guidance topped analysts' expectations and organic revenue outperform Wall Street's estimates. Still, this was a weaker quarter. The shares closed the day at $78.85, down 12.6% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy LeMaitre? Access our full analysis report here, it's free. LeMaitre's shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for LeMaitre and indicate this news significantly impacted the market's perception of the business. LeMaitre is down 14% since the beginning of the year, and at $78.70 per share, it is trading 27.1% below its 52-week high of $107.97 from November 2024. Investors who bought $1,000 worth of LeMaitre's shares 5 years ago would now be looking at an investment worth $3,113. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
30-04-2025
- Business
- Yahoo
Earnings To Watch: LeMaitre (LMAT) Reports Q1 Results Tomorrow
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results tomorrow after the bell. Here's what you need to know. LeMaitre missed analysts' revenue expectations by 0.7% last quarter, reporting revenues of $55.72 million, up 14% year on year. It was a mixed quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates but a slight miss of analysts' EPS estimates. Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting LeMaitre's revenue to grow 8% year on year to $57.75 million, slowing from the 13.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street's revenue estimates three times over the last two years. Looking at LeMaitre's peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 19.2%, beating analysts' expectations by 3.1%, and Penumbra reported revenues up 16.3%, topping estimates by 2.7%. Intuitive Surgical traded up 1.9% following the results while Penumbra was also up 7.2%. Read our full analysis of Intuitive Surgical's results here and Penumbra's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. LeMaitre is up 8.7% during the same time and is heading into earnings with an average analyst price target of $105.63 (compared to the current share price of $92.60). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
Yahoo
18-04-2025
- Business
- Yahoo
Q4 Earnings Highlights: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables
Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at LeMaitre (NASDAQ:LMAT) and the best and worst performers in the surgical equipment & consumables - specialty industry. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 0.7% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 22.3% since the latest earnings results. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $55.72 million, up 14% year on year. This print fell short of analysts' expectations by 0.7%. Overall, it was a mixed quarter for the company with a solid beat of analysts' full-year EPS guidance estimates but a slight miss of analysts' EPS estimates. Chairman/CEO George LeMaitre said, '2024 was a productive year. More reps, higher ASPs, a better GM and controlled spending produced growth in sales (+14%), op. income (+42%) & EPS (+44%). $300mm of cash provides strategic optionality.' LeMaitre pulled off the highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 19.7% since reporting and currently trades at $84.77. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it's free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.41 billion, up 25.2% year on year, outperforming analysts' expectations by 6.5%. The business had an incredible quarter with an impressive beat of analysts' sales volume and EPS estimates. Intuitive Surgical scored the biggest analyst estimates beat and fastest revenue growth among its peers. The stock is down 19.7% since reporting. It currently trades at $487.87. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it's free. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $795.4 million, up 2.8% year on year, falling short of analysts' expectations by 2.3%. It was a softer quarter as it posted a miss of analysts' constant currency revenue estimates. Teleflex delivered the weakest performance against analyst estimates and slowest revenue growth in the group. The stock is down 27.2% since the results and currently trades at $129.26. Read our full analysis of Teleflex's results here. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $442.6 million, up 11.5% year on year. This print came in 0.7% below analysts' expectations. Overall, it was a slower quarter as it also recorded a miss of analysts' full-year EPS guidance estimates. Integra LifeSciences had the weakest full-year guidance update among its peers. The stock is down 27.1% since reporting and currently trades at $16.06. Read our full, actionable report on Integra LifeSciences here, it's free. Thanks to the Fed's series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump's presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
